Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CPN1 | P15169 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.32 |
| ▸ | KDM4A | O75164 | 2/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.32 |
| ▸ | TET3 | O43151 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 2/20 | 0.31 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.31 |
| ▸ | GCK | P35557 | 1/20 | 0.30 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711544 | 1.00 | OR51E2 (0.36) | OR51E2SMN1; SMN2CPN1CPB2PIK3CD | |
| SCHEMBL7302529 | 0.84 | — | — | |
| SCHEMBL7302534 | 0.84 | — | — | |
| SCHEMBL10890162 | 0.84 | OR51E2 (0.43) | OR51E2SMN1; SMN2CPN1CPB2TET2 | |
| SCHEMBL7488763 | 0.84 | — | — | |
| SCHEMBL7495280 | 0.80 | SLC1A3 (0.40) | OR51E2SMN1; SMN2CPN1CPB2TET2 | |
| SCHEMBL3346213 | 0.80 | SLC1A3 (0.40) | OR51E2SMN1; SMN2CPN1CPB2TET2 | |
| SCHEMBL1931748 | 0.80 | SLC1A3 (0.40) | OR51E2SMN1; SMN2 | |
| SCHEMBL3353915 | 0.80 | SLC1A3 (0.40) | OR51E2SMN1; SMN2 | |
| SCHEMBL1931750 | 0.80 | SLC1A3 (0.40) | OR51E2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165452-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165452-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165452-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8389552-B2 | (S)-6-(2-(4-(cyclobutylsulfonyl)-1H-imidazol-1-yl)-3-cyclopentylpropanamido)nicotinic acid useful as a glucokinase activator | PFIZER INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389552-B2 | (S)-6-(2-(4-(cyclobutylsulfonyl)-1H-imidazol-1-yl)-3-cyclopentylpropanamido)nicotinic acid useful as a glucokinase activator | PFIZER INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389552-B2 | (S)-6-(2-(4-(cyclobutylsulfonyl)-1H-imidazol-1-yl)-3-cyclopentylpropanamido)nicotinic acid useful as a glucokinase activator | PFIZER INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8329920-B2 | Substituted imidazoles useful for treating type II diabetes | PFIZER INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329920-B2 | Substituted imidazoles useful for treating type II diabetes | PFIZER INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329920-B2 | Substituted imidazoles useful for treating type II diabetes | PFIZER INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120225910-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20110130365-A1 | Fluorinated Heteroaryls | BENBOW JOHN W | 2011-06-02 | — | — | US | disclosed |
| US-20110130365-A1 | Fluorinated Heteroaryls | BENBOW JOHN W | 2011-06-02 | — | — | US | disclosed |
| US-20110130365-A1 | Fluorinated Heteroaryls | BENBOW JOHN W | 2011-06-02 | — | — | US | disclosed |
| US-20100184777-A1 | Substituted Pyrazinone Amides | PFIZER INC | 2010-07-22 | — | — | US | disclosed |
| US-20100184777-A1 | Substituted Pyrazinone Amides | PFIZER INC | 2010-07-22 | — | — | US | disclosed |
| US-20100184777-A1 | Substituted Pyrazinone Amides | PFIZER INC | 2010-07-22 | — | — | US | disclosed |
| WO-2010029461-A1 | HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PFIZER INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010029461-A1 | HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PFIZER INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063063-A1 | Substituted Heteroaryls | PFIZER INC | 2010-03-11 | — | — | US | disclosed |
| US-20100063063-A1 | Substituted Heteroaryls | PFIZER INC | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184777-A1 | Substituted Pyrazinone Amides | GCK, GCKR, PDK2 | OR51E2 4809/4885SMN1; SMN2 4002/4885CPN1 2275/4885 |
| US-20110130365-A1 | Fluorinated Heteroaryls | GCKR, GALK1, GCK | OR51E2 4826/4885SMN1; SMN2 2551/4885CPN1 2809/4885 |
| US-20120225910-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | OR51E2 4878/4885SMN1; SMN2 3399/4885CPN1 2908/4885 |
| US-20100063063-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | OR51E2 4877/4885SMN1; SMN2 3447/4885CPN1 2931/4885 |
| US-20130165452-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | OR51E2 4877/4885SMN1; SMN2 3447/4885CPN1 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.